Increased Thrombogenic Potential of Human Monocyte-derived Macrophages Spontaneously Transformed into Foam Cells

Summary

This study investigated whether spontaneous lipid enrichment of human macrophages affects their thrombogenic potential as measured by increased production of tissue factor (TF) and plasminogen activation inhibitor types 1 and 2 (PAI-1 and PAI-2). Macrophages were obtained following a 7-day culture period of monocytes, isolated from the same donor, in autologous serum (HS) or in fetal bovine serum (FBS). Those cultured in HS underwent marked lipid accumulation relative to those cultured in FBS that was accompanied by increased production of TF and PAI-1, but not of PAI-2, and decreased production of interleukin-1β. They also contained more arachidonic and linoleic acid and lower amounts of n-3 polyunsaturated fatty acids, particularly docosahexaenoic acid (22:6). These data indicate that the transformation of macrophages into foam cells results in an increase in their thrombogenic and antifibrinolytic potential and provide a possible explanation of the thrombotic sequelae frequently consequent on plaque fissuring and disruption.

• References

• 1 Gerrity RG. The role of the monocyte in atherogenesis I: transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 1981; 103: 181-90.
• 2 Ross R. Cell biology of atherosclerosis. Ann Rev Physiol 1995; 57: 791-804.
• 3 Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-9.
• 4 Fuster V, Fallon JT, Badimon JJ, Nemerson Y. The unstable atherosclerotic plaque; clinical significance and therapeutic intervention. Thromb Haemost 1997; 78: 247-55.
• 5 Collen D, Juhan-Vague I. Fibrinolysis and atherosclerosis. Sem Thromb Haemost 1988; 14: 180-3.
• 6 Nemerson Y. Tissue factor and haemostasis. Blood 1988; 71: 1-8.
• 7 Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-79.
• 8 Wilcox JN, Smith KN, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-43.
• 9 Moreno PR, Bernardi VH, Lopez-Cuellar J, Murcia AM, Palacios IF, Gold HK, Mehran R, Sharma SK, Nemerson Y, Fuster V, Fallon JT. Macrophages, smooth muscle cells and tissue factor in unstable angina: implications for cell mediated thrombogenicity in acute coronary syndromes. Circulation 1996; 94: 3090-7.
• 10 Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997; 96: 396-9.
• 11 Saksela O, Rifkin D. Cell-associated plasminogen activation: regulation and physiological functions. Ann Rev Cell Biol 1988; 4: 93-126.
• 12 Dear AR, Medcalf L. The cellular and molecular biology of plasminogen activator inhibitor type-2. Fibrinolysis 1995; 9: 321-30.
• 13 Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
• 14 Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13: 1090-100.
• 15 Padrò T, Emeis JJ, Steins M, Schmid KW, Kienast J. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 1995; 15: 893-902.
• 16 Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, Barnathan ES. Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1432-43.
• 17 Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997; 17: 265-72.
• 18 Bradford MM. A rapid and sensitive method for the quantitation of micro-gram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
• 19 Ritchie H, Jamieson A, Booth N. Regulation, location and activity of plasminogen activator inhibitor 2 (PAI-2) in peripheral blood monocytes, macrophages and foam cells. Thromb Haemost 1997; 77: 1168-73.
• 20 Hamilton JA, Whitty GA, Wojta J, Gallichio M, McGrath K, Ianches G. Regulation of plasminogen activator inhibitor-1 levels in human monocytes. Cell Immunol 1993; 152: 7-11.
• 21 Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 1989; 9: 2752-5.
• 22 Lyberg T, Prydz H. Phorbol esters induce synthesis of thromboplastin activity in human monocytes. Biochem J 1981; 194: 699-706.
• 23 Conkling PR, Greenberg CS, Weinberg JB. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 1988; 72: 128-33.
• 24 Marangoni F, Angeli MT, Colli S, Eligini S, Tremoli E, Sirtori CR, Galli C. Changes of n-3 and n-6 fatty acids in plasma and circulating cells of normal subjects, after prolonged administration of 20: 5 (EPA) and 22: 6 (DHA) ethyl esters and prolonged washout. Biochim Biophys Acta 1993; 1210: 55-62.
• 25 Castellote JC, Grau E, Linde MA, Pujol-Moix N, Rutlant ML. Detection of both type 1 and type 2 plasminogen activator inhibitors in human monocytes. Thromb Haemost 1990; 63: 67-71.
• 26 Garner B, Baoutina A, Dean RT, Jessup W. Regulation of serum-induced lipid accumulation in human monocyte-derived macrophages by IFN-γ. Correlations with apolipoprotein E production, lipoprotein lipase activity and LDL receptor-related protein expression. Atherosclerosis 1997; 128: 47-58.
• 27 Ritchie H, Jamieson A, Booth N. Peripheral blood monocyte synthesis of plasminogen activator inhibitor 2 in response to native and modified LDL. Thromb Haemost 1995; 74: 1521-7.
• 28 Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067-73.
• 29 Sironi L, Mussoni L, Prati L, Baldassarre D, Camera M, Banfi C, Tremoli E. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol 1996; 16: 89-96.
• 30 Schuff-Werner P, Claus G, Armstrong VW, Kostering H, Seidel D. Enhanced procoagulatory activity (PCA) of human monocytes/macrophages after in vitro stimulation with chemically modified LDL. Atherosclerosis 1989; 78: 109-12.
• 31 Lesnik P, Rouis M, Skarlatos S, Kruth HS, Chapman MJ. Uptake of exogenous free cholesterol induces upregulation of tissue factor expression in human monocyte-derived macrophages. Proc Natl Acad Sci USA 1992; 89: 10370-6.
• 32 Brand K, Banka CL, Mackman N, Terkeltaub RA, Fan ST, Curtiss L. Oxidized LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes. Arterioscler Thromb 1994; 14: 790-7.
• 33 Tipping PG, Malliaros J, Holdsworth SR. Procoagulant activity expression by macrophages from atheromatous vascular plaques. Atherosclerosis 1989; 79: 237-43.
• 34 Tipping PG, Davenport P, Gallicchio M, Filonzi EF, Apostolopoulos J, Wojta J. Atheromatous plaque macrophages produce plasminogen activator inhibitor type-1 and stimulate its production by endothelial cells and vascular smooth muscle cells. Am J Pathol 1993; 143: 875-84.
• 35 Scheibenbogen C, Moser H, Krause S, Andreesen R. Interferon-gamma-induced expression of tissue factor activity during human monocyte to macrophage maturation. Haemostasis 1992; 22: 173-8.
• 36 Jungi TW, Miserez R, Brcic M, Pfister H. Change in sensitivity to lipopolysaccharide during the differentiation of human monocytes to macrophages in vitro. Experientia 1994; 50: 110-4.
• 37 Fong LG., Fong TAT, Cooper AD. Inhibition of lipopolysaccharide-induced interleukin-1β mRNA expression in mouse macrophages by oxidized low density lipoprotein. J Lipid Res 1991; 32: 1899-909.
• 38 Nagornev VA, Maltseva SV. The phenotype of macrophages which are not transformed into foam cells in atherogenesis. Atherosclerosis 1996; 121: 245-51.
• 39 Banfi C, Risé P, Mussoni L, Galli C, Tremoli E. Linoleic acid enhances the secretion of plasminogen activator inhibitor type 1 by HepG2 cells. J Lip Res 1997; 38: 860-9.
• 40 Durand P, Prost M, Blache D. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. Atherosclerosis 1996; 121: 231-43.
• 41 Dustin LB, Soberman R, Shea CM, Lu CY. Docosahexaenoic acid, a constituent of rodent fetal serum and fish oil diets, inhibits acquisition of macrophage tumoricidal function. J Immunol 1990; 144: 4888-97.
• 42 Khair-El-Din TA, Sicher SC, Vazquez MA, Wright WJ, Lu CY. Docosahexaenoic acid, a major constituent of fetal serum and fish oil diets, inhibits IFNγ-induced Ia-expression by murine macrophages in vitro. J Immunol 1995; 154: 1296-306.
• 43 Ohata T, Fukuda K, Takahashi M, Sugimura T. Wakabayashi. Suppression of nitric oxide production in lipopolysaccharide-stimulated macrophage cells by omega-3 polyunsaturated fatty acids. Japan J Canc Res 1997; 88: 234-7.
• 44 Robinson DR, Urakaze M, Huang R, Taki H, Sugiyama E, Knoell CT, Xu L, Yeh ET, Auron PE. Dietary marine lipids suppress continuous expression of interleukin-1β gene transcription. Lipids 1996; 31: 23-31.
• 45 Felton CV, Crook D, Davies MJ, Oliver MF. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vasc Biol 1997; 17: 1337-45.